



Osteoarthritis: Molecular Pathways and Novel Therapeutic Strategies

Guest Editors:

Dr. Antonia Patruano

Dr. Teresa Paolucci

Dr. Mirko Pesce

Dr. Andrea Pantalone

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editors

Osteoarthritis (OA) is a prevalent and degenerative joint disorder characterized by the progressive deterioration of joint cartilage and the surrounding structures. It is the most common form of arthritis and often affects weight-bearing joints such as the knees, hips. Osteoarthritis (OA) exhibits a spectrum of clinical phenotypes, reflecting the heterogeneous nature of this prevalent joint disorder: (1) Chronic Pain Phenotype (Emphasizes central mechanisms, such as central sensitization; Characterized by persistent pain, potentially influencing treatment strategies); (2) Inflammatory Phenotype (Marked by elevated levels of inflammatory biomarkers); (3) Metabolic Syndrome Phenotype (Exhibits a high prevalence of obesity, diabetes, and metabolic disturbances); (4) Bone and Cartilage Metabolism Phenotype (Involves alterations in local tissue metabolism); (5) Mechanical Overload Phenotype (Primarily characterized by varus malalignment and medial compartment disease); (6) Minimal Joint Disease Phenotype (Characterized by minor clinical symptoms with slow progression).





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)